Skip to content
Educational information only. Not medical advice. We sell nothing and take no affiliate money.
By /
Unverified peptide productNo published researchNot FDA approved

Pentadeca Arginate (PDA)

Pentadeca arginate

Last reviewed October 27, 2026 · 9 sources · Written for general readers · Compare with another compound →

The bottom line

Pentadeca arginate, or PDA, is a name, not a studied drug. We searched the medical literature and FDA records and found no study testing it in cells, animals or people, so every claim made for it, from faster healing to being a safer BPC-157, is untested. Even BPC-157 itself has almost no reliable human data.

Where the evidence stands

What it is

Pentadeca arginate, or PDA, is a name, not a studied drug. The name suggests a salt form of BPC-157, a 15 amino acid peptide, made with the amino acid arginine. No published scientific paper we found confirms what is actually in products sold under this name.[1]

A search of Europe PMC, a database that includes PubMed, turned up only one article that mentions pentadeca arginate at all: a 2026 review about peptides in bone and joint medicine. That review is not a study of PDA, and it says lab and animal work on such peptides looks promising but clinical trials are lacking.[1][2]

PDA does not appear anywhere on FDA's lists of substances nominated for pharmacy compounding.[3]

Name
Pentadeca Arginate (PDA) (Pentadeca arginate)
Other names
PDA, pentadecapeptide arginate
Type
Unverified peptide product

How it works

Nobody has published how PDA works, because nobody has published a study of PDA.

  • No study shows that a product called PDA behaves like BPC-157 in the body.[1]
  • FDA says different salt forms of a peptide can differ in how they dissolve, how stable they are and how they behave, and it treats each form as a separate substance. Its 2026 review covered only plain BPC-157 and BPC-157 acetate and never mentions an arginate form.[4]

Any claim about how PDA works is a guess, not a finding.

What the research shows

We keep animal and human evidence apart. A result in animals is a reason to study something in people, not proof that it works in people.

Animal and lab studies

No animal studies found

  • We found no published animal or lab study of pentadeca arginate.[1]

Limit: Animal results for BPC-157 cannot be assumed to apply to an untested product with a different name.

Human studies

No human studies at all

  • No study has given PDA to people, so there is no record of what users experience, how well it works, or what side effects it causes.[1]
  • For comparison, FDA reviewers in 2026 found only five small, short clinical studies of BPC-157 itself, and none used the injections under the skin that are most common online.[4]

Limit: With no human data, nobody can say whether PDA is safe or does anything.

Claims check

The most common claims about this compound, and what studies actually found. Verdicts rate the evidence, not whether you should use it.

Heals tendons, joints and sports injuries

Not tested

No study of PDA exists.[1] For BPC-157 itself, tendon healing has been shown only in animals, and the main human report is a look back at 17 people given knee injections at one clinic with no comparison group.[4][5]

Heals the gut and calms inflammation

Not tested

No study of PDA exists.[1] For BPC-157, the only randomized human study, in about 53 people with ulcerative colitis given an enema for two weeks, found no statistically significant benefit over placebo.[4]

More stable or better absorbed than BPC-157

Not tested

No published data compare PDA with BPC-157 for stability or absorption.[1] FDA notes that different salt forms can behave differently and must be judged on their own data, which do not exist for an arginate form.[4]

Relieves pain

Not tested

No study has measured pain in anyone given PDA.[1] Uncontrolled reports for BPC-157, such as the 17 person knee chart review, cannot separate the peptide from placebo effects or natural recovery.[5]

A legal or safer alternative to BPC-157

Not tested

No safety study of PDA exists, and it is not on any FDA compounding list.[1][3] FDA says research only labels do not make an unapproved drug legal to sell for people, and WADA bans unapproved substances like this in sport.[6][7]

Known risks and side effects

  • Completely untested. There is no published safety data of any kind for PDA, in cells, animals or people.[1]
  • Unknown contents. No public standard defines what PDA is, so a vial labeled PDA could contain anything. FDA has never checked these products for identity, purity or sterility.[3]
  • Immune reactions. FDA has said that for BPC-157 there is little or no safety information for the proposed routes of use, and its reviewers flagged a possible immune reaction to injected peptides. No one has checked whether PDA products carry the same risk.[8][4]
  • Research use labels do not protect you. FDA has said in warning letters that labels like "for research only" or "not for human use" do not change that a product sold for people is an unapproved drug.[6]
  • Banned in sport. WADA's S0 category bans any drug with no current government approval for human use and names BPC-157 as an example. That rule would cover PDA too.[7]

Regulatory status

Today: PDA is not an approved drug and does not appear on any FDA compounding list.[3] BPC-157, the peptide its name points to, received an 8 to 6 advisory committee vote in favor of compounding in July 2026, against FDA staff advice, but FDA has not acted on it and PDA was not part of that review.[9]

  1. FDA warned an online seller of research labeled products that research only labels do not excuse selling unapproved drugs meant for people.[6]
  2. FDA's updated compounding category lists still did not include pentadeca arginate.[3]
  3. FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 with one abstention to recommend BPC-157 for the compounding list. PDA was not on the agenda.[9]

Sources

  1. Europe PMC. Literature search for "pentadeca arginate", "pentadecapeptide arginate" and "BPC-157 arginate" (1 result). Searched October 29, 2026. Europe PMC search
  2. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. JAAOS Glob Res Rev. 2026;10(1). PMID 41490200
  3. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (category lists). Updated May 14, 2026. FDA 503A category lists
  4. U.S. Food and Drug Administration. FDA Briefing Document for BPC-157-Related Bulk Drug Substances. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. FDA briefing document
  5. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435
  6. U.S. Food and Drug Administration. Warning Letter to Pinnacle Professional Research dba Pinnacle Peptides, MARCS-CMS 719337. December 12, 2025. FDA warning letter
  7. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. Effective 1 January 2026. WADA 2026 List, S0
  8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. FDA safety risks page
  9. Steinzor P. FDA Panel Backs 6 Peptides for Compounding. The American Journal of Managed Care. July 31, 2026. PCAC vote coverage
Medical disclaimer

This page is educational information only. It is not medical advice and does not replace care from a licensed medical provider. Do not use this page to decide whether to take any substance. Talk to a licensed medical provider first.

Found an error or a newer study? We correct pages fast.

Report a correction →
Scroll to Top